Anbenitamab Biosimilar - Research Grade

Human

ERBB2

>1mg/ml

IgG1 - kappa

CHO Cells

Trastuzumab Biosimilar - Research Grade (ICH4013), Ado-Trastuzumab Emtansine Biosimilar - Research Grade (ICH4014), Pertuzumab Biosimilar - Research Grade (ICH4030), Margetuximab Biosimilar - Research Grade (ICH5057), Calotatug Biosimilar - Research Grade (ICH5421), Coprelotamab Biosimilar - Research Grade (ICH5448), Disitamab Biosimilar - Research Grade (ICH5482), Gancotamab Biosimilar - Research Grade (ICH5562), Lunaxafusp Biosimilar - Research Grade (ICH5662), Timigutuzumab Biosimilar - Research Grade (ICH5925), Zanidatamab Biosimilar - Research Grade (ICH6002)

https://www.imgt.org/mAb-DB/

ICH3002

P04626

Blue ice

ICH5344 is a research-grade biosimilar of Anbenitamab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. Anbenitamab (also known as KN026) is a HER2-directed antibody built around the ERBB2 (HER2) antigen. Notably, the originator is a biparatopic bispecific molecule that engages two non-overlapping epitopes on HER2, combining a trastuzumab-like binding domain (HER2 domain IV) with a pertuzumab-like binding domain (HER2 domain II). This product is intended as a target-defined analog for functional and in-vitro work, not for clinical or therapeutic use. It is offered at low endotoxin (research grade less than 1 EU/mg) and is available in bulk (mg to g) quantities to support in-vitro assays, binding and neutralization studies, ADCC/CDC characterization, and use as a reference or control reagent. Because HER2 is a human tumor antigen and the analog is directed against it, this reagent is most suited to cell-based and biochemical assays rather than mouse in-vivo dosing. Reported isotype is human IgG1, kappa. All content here is provided for ichor.bio to review. The target, ERBB2/HER2 (UniProt P04626), is a receptor tyrosine kinase of the EGFR/ErbB family. Unlike other family members, HER2 has no known direct high-affinity ligand and functions primarily as a preferred heterodimerization partner, most potently with HER3. Dimerization drives PI3K/AKT and RAS/MAPK signaling that promotes proliferation, survival, and, when amplified or overexpressed, oncogenic transformation. HER2 amplification is a well-established driver in subsets of breast and gastric/gastroesophageal cancers. Anbenitamab's biparatopic design engages HER2 domain IV and domain II simultaneously, blocking ligand-independent signaling and heterodimerization, promoting receptor clustering and internalization, and enhancing immune-mediated killing via ADCC and CDC. These mechanisms underpin the antibody's relevance as a research tool for interrogating HER2 biology.

Metastatic lymph node gene 19 protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, Receptor tyrosine-protein kinase erbB-2, HER2, NEU, NGL

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Anbenitamab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Anbenitamab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Anbenitamab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Anbenitamab that binds ERBB2.